Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BELLWAVE-011: nemtabrutinib versus investigator's choice of ibrutinib or acalabrutinib in previously untreated CLL/SLL
MOH_2023-11-07_013030Phase 3Recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of nemtabrutinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) (2 arms), sponsored by Merck & Co. Started Nov 2023; status: recruiting.
02
Drugs
nemtabrutinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on MOH_2023-11-07_013030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-11-07_013030.